ArticleScientific reports2025
The role of immune cells in cirrhosis: evidence from a two-sample Mendelian randomization study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluation methods of hepatic steatosis: From conventional techniques to emerging biomarkers.World journal of hepatology · 2026Review
- Gut Microbiota and Primary Liver Cancer: Mendelian Randomization and Network Pharmacology Used to Predict Potential Therapeutic Intervention With Traditional Chinese Medicine.International journal of genomics · 2026Article
- Cirrhosis severity modulates proteomic and immune landscapes in hepatocellular carcinoma.Npj gut and liver · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The burden on social and economic development caused by cirrhosis, a common terminal pathological process in most liver diseases, is substantial. The liver, being the outstanding immune organ in the body, thus emphasizing the critical role of immune cells in the pathogenesis and progression of cirrhosis.However, there is a paucity of studies investigating the correlation between immunophenotype and cirrhosis. The Mendelian randomization(MR) study was employed to explore relationships between these factors, aiming to provide new directions and insights for clinical research. Methods The genetic data associated with cirrhosis from genome-wide association studies (GWAS) were obtained from the FinnGen R10 database.Inverse variance weighting (IVW) completing with MR-Egger, weighted mode, simple mode, and weighted median were adopted to enhance the robustness of our analysis. Finally, the potential association between immunophenotypes and cirrhosis was clarified. Results Fourteen immunophenotypes closely associated with cirrhosis were identified. Specifically, there were four distinct types of B cells, seven distinct types of Myeloid cells, one classical dendritic cell (cDC), CCR2 on CD62L + myeloid DC; one type of Treg cell, CD39 on CD39 + secreting Treg; one type of TBNK cells, SSC-A on NK. The robustness of the MR Study was further confirmed through comprehensive evaluations of pleiotropy and heterogeneity. Conclusion The MR study is the pioneering effort to offer informative and comprehensive data supporting the association between immunophenotypes and cirrhosis. These findings have significant implications for tailoring individualized treatment strategies, optimizing cirrhosis management, and enhancing overall survival.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.